Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

Other News

Harvey Weinstein wants to move trial out of NYC

Aug 21, 2019

NEW YORK — A lawyer for Harvey Weinstein has asked that the disgraced movie mogul's upcoming criminal trial be moved out of New York City, saying he can't get a fair trial. In a longshot motion filed with the state appellate court on Friday, attorney Arthur Aidala suggested the trial be moved to upstate Albany County or Suffolk County on Long Island. Aidala cited the intense media coverage and the circuslike atmosphere surrounding Weinstein's past court appearances in Manhattan. The 67-year-old Weinstein is charged with raping a woman in 2013 and performing a forcible sex act on a different woman...

Cowboys' Elliott won't face criminal charge in Vegas scuffle

Aug 21, 2019

LAS VEGAS — Dallas Cowboys star running back Ezekiel Elliott won't face criminal charges after scuffling with a music festival security guard in Las Vegas. Prosecutor Steve Wolfson said Tuesday the findings of a police investigation "lacked prosecutorial merit." The NFL said last month that Elliott didn't violate league personal conduct rules and wouldn't face suspension. Elliott was handcuffed but not arrested after police said he pushed a security guard to the ground at the event last May at Las Vegas Motor Speedway. Cellphone video obtained by celebrity website TMZ showed an event staffer stumbling over a parking barrier after...

Review: In 'Brittany Runs a Marathon,' a breakout for Bell

Aug 21, 2019

Getting in shape and putting your life together usually, at the movies, passes in a montage. But for many, the non-Rocky legions of us, such transformations require more than inspiring theme music and lifting weights in the snow. And for the Brittany (Jillian Bell) of "Brittany Runs a Marathon," that's especially true. Brittany is an aimless and broke 20-something in New York who's startled when her attempt to pry an Adderall prescription from a doctor (Patch Darragh) turns into a recommendation to improve her body mass index. He suggests she changes her hard-drinking lifestyle and lose about 50 pounds. After...

Calls for action from Twitter after Pogba gets racist abuse

Aug 21, 2019

LONDON — Manchester United defender Harry Maguire called on social media companies to require users to verify their identities after teammate Paul Pogba was targeted on Twitter with racial abuse. Racially offensive tweets about Pogba were posted after his penalty kick was saved in United's 1-1 draw at Wolverhampton Wanderers in the English Premier League on Monday. The 20-time English champions said they "encourage social media companies to take action in these cases" and Maguire offered a solution. "Every account that is opened should be verified by a passport/driving license. Stop these pathetic trolls making numerous accounts to abuse people,"...

Pell's appeal pitted word of former choirboy against priest

Aug 21, 2019

CANBERRA, Australia — Cardinal George Pell's appeal against his convictions for child molestation was largely a question of who the jury should have believed, his accuser or a senior priest whose church role was likened to Pell's bodyguard. Pell's accuser was a 13-year-old choirboy when he alleged that he was abused by then-Melbourne Archbishop Pell at the city's St. Patrick's Cathedral in December 1996 and February 1997. Monsignor Charles Portelli was a master of ceremonies at the 11 a.m. Sunday Masses where the choir sang. A chorister in the 1990s, David Dearing, told police that Portelli, Pell's right-hand man, was...

Enter Wicked dives into the Entertainment World seeking to report the hot topics going on with celebrities.

Contact us: sales@enterwicked.com